SK Telecom and SK Biopharm Discover Effective Substances for Treating Incurable Cancers Using AI

SK Telecom and SK Biopharm have identified initial effective substances for targeted cancer treatment using AI. The companies collaborated to develop candidate binders that target the ROR1 protein, a key marker in various blood and solid tumors. By integrating AI-driven molecular design and machine learning techniques, they reduced the typical 1-2 year drug discovery timeline by over 60% in just five months. The breakthrough demonstrates AI's potential to accelerate early-stage drug development while maintaining scientific rigor.